Up next

Autoplay

Safety and efficacy of single agent rovalpituzumab tesirine in small cell lung cancer (SCLC)

1 Views • 07/14/23
Share
Embed
administrator
administrator
Subscribers
0

Press brief by Charles Rudin, MD, PhD of the Memorial Sloan Kettering Cancer Center, New York, NY, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay